市場調查報告書

中國的重組人體促血小板生成素市場分析

Investigation Report on China's Recombinant Human Thrombopoietin Market, 2019-2023

出版商 China Research and Intelligence 商品編碼 910645
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的重組人體促血小板生成素市場分析 Investigation Report on China's Recombinant Human Thrombopoietin Market, 2019-2023
出版日期: 2019年09月04日內容資訊: 英文 30 Pages
簡介

本報告提供中國國內的基因改造人體促血小板生成素市場相關分析,彙整產品的概要、功效和授權情形,整體市場規模趨勢預測 (過去、今後5年份),市場價格的變化及預測,主要企業的簡介與市場佔有率等資訊,為您概述為以下內容。

第1章 重組人體促血小板生成素的相關概念

  • 重組人體促血小板生成素的適應症
  • 中國的重組人體促血小板生成素市場發展
  • 中國國內的重組人體促血小板生成素的專利、核准趨勢

第2章 中國國內的重組人體促血小板生成素的銷售量

  • 重組人體促血小板生成素的銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 重組人體促血小板生成素的銷售量
    • 整體銷售量
    • 各地區的銷售量
  • 重組人體促血小板生成素的銷售量:各劑型
    • 注射
    • 各劑型的開發趨勢

第3章 中國的重組人體促血小板生成素市場:主要製造商分析

  • 主要廠商的市場佔有率
    • 銷售額為基礎
    • 銷售量為基礎
  • Shenyang Sunshine Pharmaceutical Co., Ltd.
    • 企業簡介
    • 重組人體促血小板生成素的近幾年的銷售量

第4章 中國國內的重組人體促血小板生成素的市場價格

  • Shenyang Sunshine Pharmaceutical Co., Ltd. (TPIAO)
  • 重組人體促血小板生成素的價格趨勢

第5章 中國的重組人體促血小板生成素市場未來展望

  • 對市場的影響要素
    • 推動市場要素與市場機會
    • 威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 1909404

Description

In recent years, the incidence of thrombopenia in China keeps increasing. Thrombopenia is often seen in hematologic diseases such as primary immune thrombopenia, leukemia and aplastic anemia as well as in connective tissue diseases, liver diseases and tumor chemotherapy. Thrombopenia may also be congenital or drug-induced. Primary immune thrombopenia is a clinically common hemorrhagic disease, accounting for 1/3 of hemorrhagic diseases. The annual incidence of primary immune thrombopenia is 5/100,000 to 10/100,000. The number of patients with thrombopenia in China is increasing by over 100,000 every year. Research shows that 20% to 30% of patients receiving chemotherapy have obvious thrombopenia. The incidence of thrombopenia is 81.80% among patients receiving single-agent carboplatin chemotherapy, 58.20% among patients receiving carboplatin combination chemotherapy, 64.40% among patients receiving gemcitabine chemotherapy and 59.30% among patients receiving paclitaxel chemotherapy.

Using thrombopoietin such as Recombinant Human Thrombopoietin is one of the ways to treat thrombopenia. In 2005, Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. (trade name: TPIAO) was approved to be sold in China. By Aug. 2019, it is the only approved Recombinant Human Thrombopoietin product on the Chinese market.

In China, Recombinant Human Thrombopoietin applies to the treatment of patients with thrombopenia (platelet count < 50×109/L) caused by solid tumor chemotherapy when doctors regard it necessary to increase platelet count. It is also used to assist the treatment of patients who have idiopathic thrombocytopenic purpura with platelet count below 20×109/L when glucocorticoids do not work. It is only applied to patients with thrombopenia and patients facing the increasing risk of bleeding. It is not used to increase platelet count to the normal level.

According to CRI's market survey, the sales value of Recombinant Human Thrombopoietin kept rising after the drug was launched in China. In 2017, it reached CNY 523 million, representing a CAGR of 27.90% from 2013 to 2017.

CRI expects that as the number of patients with thrombopenia increases in China, the demand for Recombinant Human Thrombopoietin will also increase. Considering the high growth rate of the Recombinant Human Thrombopoietin market, Recombinant Human Thrombopoietin products by other enterprises will probably be approved to be launched in China in the next few years.

Table of Contents

1 Relevant Concepts of Recombinant Human Thrombopoietin

  • 1.1 Indications for Recombinant Human Thrombopoietin
  • 1.2 Development of Recombinant Human Thrombopoietin in China
  • 1.3 Patents and Government Approval on Recombinant Human Thrombopoietin in China

2 Sales of Recombinant Human Thrombopoietin in China, 2013-2017

  • 2.1 Sales Value of Recombinant Human Thrombopoietin
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Recombinant Human Thrombopoietin
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Recombinant Human Thrombopoietin by Dosage Form in China, 2013-2017
    • 2.3.1 Injections
    • 2.3.2 Development Trend of Dosage Forms

3 Analysis on Major Manufacturer of Recombinant Human Thrombopoietin in China, 2013-2017

  • 3.1 Market Share of Major Manufacturer of Recombinant Human Thrombopoietin
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Shenyang Sunshine Pharmaceutical Co., Ltd.
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. In China

4 Prices of Recombinant Human Thrombopoietin in China, 2017-2018

  • 4.1 Shenyang Sunshine Pharmaceutical Co., Ltd. (TPIAO)
  • 4.2 Price Trend of Recombinant Human Thrombopoietin

5 Prospect of China's Recombinant Human Thrombopoietin Market, 2019-2023

  • 5.1 Factors Influencing Development of China's Recombinant Human Thrombopoietin Market
    • 5.1.1 Driving Forces and Market Opportunities
    • 5.1.2 Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

Selected Charts

  • Chart Patents on Recombinant Human Thrombopoietin in China
  • Chart Government Approval on Recombinant Human Thrombopoietin in China
  • Chart Sales of Recombinant Human Thrombopoietin in China, 2013-2017
  • Chart Sales Value of Recombinant Human Thrombopoietin in Parts of China, 2013-2017
  • Chart Sales Volume of Recombinant Human Thrombopoietin in China, 2013-2017
  • Chart Sales Volume of Recombinant Human Thrombopoietin in Parts of China, 2013-2017
  • Chart Sales Value of Recombinant Human Thrombopoietin Injections in China, 2013-2017
  • Chart Sales Volume of Recombinant Human Thrombopoietin Injections in China, 2013-2017
  • Chart Market Share of Manufacturer of Recombinant Human Thrombopoietin by Sales Value in China, 2013-2017
  • Chart Sales Value of Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. In China, 2013-2017
  • Chart Prices of Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. (TPIAO) in Parts of China, 2017-2018
  • Chart Forecast on Sales Value of Recombinant Human Thrombopoietin in China, 2019-2023
Back to Top